Abstract
Over a hundred years has passed since the discovery of the "magic bullet" serum therapy by Kitasato and Behring, the first ever therapeutic use of antibodies. More than 80 years later, the investigation of immunoglobulin structure and function and the development of cell and molecular biology introduced the production of monoclonal antibodies (MoAbs). In the 35 years since the first process for creating MoAbs was introduced, they have remained the centerpiece of the growing biotechnology and pharmaceutical industry. Herein, I review the history, development, and clinical settings of therapeutic MoAbs that have had a significant impact on life-saving medicine.
Original language | English |
---|---|
Pages (from-to) | 37-46 |
Number of pages | 10 |
Journal | Keio Journal of Medicine |
Volume | 60 |
Issue number | 2 |
DOIs | |
Publication status | Published - 2011 Jun |
Keywords
- Immunoglobulin
- Molecular target therapy
- Monoclonal antibody
ASJC Scopus subject areas
- Medicine(all)